Recce Pharmaceuticals Ltd. (AU:RCE)
ASX:RCE
Want to see AU:RCE full AI Analyst Report?
RCE Stock Chart & Stats
AU$0.41
AU$0.00(0.00%)
At close: 4:00 PM EST
AU$0.41
AU$0.00(0.00%)
Day’s Range― - ―
52-Week RangeAU$0.29 - AU$0.73
Previous CloseN/A
Volume21.12K
Average Volume (3M)154.69K
Market Cap
AU$138.81M
Enterprise ValueAU$158.38M
Total Cash (Recent Filing)AU$602.99K
Total Debt (Recent Filing)AU$11.26M
Price to Earnings (P/E)―
Beta0.97
Next Earnings
Aug 28, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.12
Shares Outstanding289,183,400
10 Day Avg. Volume112,630
30 Day Avg. Volume154,688
Financial Highlights & Ratios
PEG Ratio0.34
Price to Book (P/B)-22.52
Price to Sales (P/S)9.15
P/FCF Ratio-3.36
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.06
Revenue Forecast (FY)AU$4.25M
Bulls Say, Bears Say
Bulls Say
Improving Free Cash FlowA 51.97% free cash flow growth rate signals improving cash generation capacity from operations and investments. Over 2-6 months this can extend runway, reduce near-term funding needs, and provide more flexibility to progress clinical programs without immediate dilution if sustained.
Operational Efficiency (ROE)A positive 7.02% ROE suggests the company is extracting some value from equity capital despite losses and negative equity. This indicates disciplined allocation of resources and potential for incremental value creation from R&D investment if clinical advances continue.
Strategic Focus On High-Need Anti-InfectivesFocused portfolio on broad-spectrum anti-infectives for sepsis, bacteremia and wound infections addresses structural demand driven by antibiotic resistance. Multiple formulations (IV, oral, topical) diversify development paths and bolster long-term commercial opportunity if trials succeed.
Bears Say
Severe Losses & Negative MarginsExtremely negative margins reflect that costs (notably R&D and clinical expenses) far exceed revenues. This structural unprofitability requires sustained external funding, increases dilution risk, and constrains the company's ability to self-fund multi-stage clinical programs over the medium term.
Negative Equity And High LeverageNegative equity and a materially adverse debt-to-equity metric signal balance-sheet fragility. This reduces financial flexibility, raises refinancing and covenant risk, and can hinder strategic options such as partnerships or acquisitions that require strong counterparty balance sheets.
Weak Operating Cash GenerationA negative operating cash flow to net income ratio shows core operations are not converting losses into cash. Reliance on non-operational cash sources to fund development is structurally risky, making timelines and program continuity sensitive to capital markets and financing availability.
Recce Pharmaceuticals Ltd. News
RCE FAQ
What was Recce Pharmaceuticals Ltd.’s price range in the past 12 months?
Recce Pharmaceuticals Ltd. lowest share price was AU$0.28 and its highest was AU$0.73 in the past 12 months.
What is Recce Pharmaceuticals Ltd.’s market cap?
Recce Pharmaceuticals Ltd.’s market cap is AU$138.81M.
When is Recce Pharmaceuticals Ltd.’s upcoming earnings report date?
Recce Pharmaceuticals Ltd.’s upcoming earnings report date is Aug 28, 2026 which is in 68 days.
How were Recce Pharmaceuticals Ltd.’s earnings last quarter?
Recce Pharmaceuticals Ltd. released its earnings results on Feb 27, 2026. The company reported -AU$0.057 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.057.
Is Recce Pharmaceuticals Ltd. overvalued?
According to Wall Street analysts Recce Pharmaceuticals Ltd.’s price is currently Overvalued.
Does Recce Pharmaceuticals Ltd. pay dividends?
Recce Pharmaceuticals Ltd. does not currently pay dividends.
What is Recce Pharmaceuticals Ltd.’s EPS estimate?
Recce Pharmaceuticals Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Recce Pharmaceuticals Ltd. have?
Recce Pharmaceuticals Ltd. has 289,183,400 shares outstanding.
What happened to Recce Pharmaceuticals Ltd.’s price movement after its last earnings report?
Recce Pharmaceuticals Ltd. reported an EPS of -AU$0.057 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -0.917%.
Which hedge fund is a major shareholder of Recce Pharmaceuticals Ltd.?
Currently, no hedge funds are holding shares in AU:RCE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Recce Pharmaceuticals Ltd. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
38.63%
12-Months-Change
Fundamentals
Return on Equity
279.21%
Trailing 12-Months
Asset Growth
-51.48%
Trailing 12-Months
Company Description
Recce Pharmaceuticals Ltd.
Recce Pharmaceuticals Ltd operates as a biotechnology enterprise, concentrating on the research, advancement, and market introduction of synthetic anti-infective treatments across Australia, the United States, and the United Kingdom. The company's foremost developmental drug, RECCE 327, is intended to address blood infections and sepsis caused by E. coli and S. aureus bacteria, including their antibiotic-resistant variants. Additionally, Recce is progressing RECCE 529, a synthetic anti-infective targeting viral illnesses, and RECCE 435, another synthetic polymer anti-infective. Founded in 2007, the firm, which was initially named Recce Limited, officially became Recce Pharmaceuticals Ltd in November 2017. Its corporate headquarters are situated in Sydney, Australia.
Technical Analysis
Amplia Therapeutics
―
Imugene
―
Alterity Therapeutics
―
Prescient Therapeutics Limited
―
Arovella Therapeutics Limited
―
Options Prices
Currently, No data available
---